Judith A Aberg

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. doi request reprint Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America
    Judith A Aberg
    New York University School of Medicine, Bellevue Hospital Center, New York, USA
    Clin Infect Dis 49:651-81. 2009
  2. pmc Cardiovascular complications in HIV management: past, present, and future
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University School of Medicine, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 50:54-64. 2009
  3. pmc Lipid management in patients who have HIV and are receiving HIV therapy
    Judith A Aberg
    Bellevue Hospital Center, AIDS Clinical Trials Unit, New York University School of Medicine, 550 First Avenue, BCD 5 Room 558, NY 10016, USA
    Endocrinol Metab Clin North Am 38:207-22. 2009
  4. pmc Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks
    Judith A Aberg
    Bellevue Hospital Center at New York University School of Medicine, New York, USA
    AIDS Res Hum Retroviruses 28:1184-95. 2012
  5. pmc Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy
    Michelle S Cespedes
    Division of Infectious Diseases and Immunology, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 62:550-4. 2013
  6. pmc Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108
    Judith A Aberg
    New York University, New York, New York, USA
    AIDS 20:725-9. 2006
  7. ncbi request reprint Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York 10016, USA
    Clin Infect Dis 39:609-29. 2004
  8. doi request reprint Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America
    Judith A Aberg
    Division of Infectious Diseases and Immunology, New York University School of Medicine, Bellevue Hospital Center, New York
    Clin Infect Dis 58:1-10. 2014
  9. ncbi request reprint A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 21:757-67. 2005
  10. ncbi request reprint Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers
    Marshall J Glesby
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 78:143-53. 2005

Collaborators

Detail Information

Publications28

  1. doi request reprint Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America
    Judith A Aberg
    New York University School of Medicine, Bellevue Hospital Center, New York, USA
    Clin Infect Dis 49:651-81. 2009
    ..HIV-infected persons should be managed and monitored for all relevant age- and gender-specific health problems. New information based on publications from the period 2003-2008 has been incorporated into this document...
  2. pmc Cardiovascular complications in HIV management: past, present, and future
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University School of Medicine, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 50:54-64. 2009
    ..These benefits of antiretroviral therapy have been demonstrated in studies comparing the superior efficacy of continuous vs. intermittent HAART...
  3. pmc Lipid management in patients who have HIV and are receiving HIV therapy
    Judith A Aberg
    Bellevue Hospital Center, AIDS Clinical Trials Unit, New York University School of Medicine, 550 First Avenue, BCD 5 Room 558, NY 10016, USA
    Endocrinol Metab Clin North Am 38:207-22. 2009
    ..Evidence for these two strategies is discussed...
  4. pmc Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks
    Judith A Aberg
    Bellevue Hospital Center at New York University School of Medicine, New York, USA
    AIDS Res Hum Retroviruses 28:1184-95. 2012
    ..This first pilot comparison in HIV-1-infected subjects suggests that DRV/r has a metabolic profile similar to ATV/r over 48 weeks of treatment. Further randomized studies are warranted...
  5. pmc Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy
    Michelle S Cespedes
    Division of Infectious Diseases and Immunology, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 62:550-4. 2013
    ..Median ratio of cord blood/maternal APV levels was 0.27, and all infants were HIV negative. FPV/ritonavir during pregnancy was well tolerated and led to virologic suppression...
  6. pmc Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108
    Judith A Aberg
    New York University, New York, New York, USA
    AIDS 20:725-9. 2006
    ..Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia...
  7. ncbi request reprint Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York 10016, USA
    Clin Infect Dis 39:609-29. 2004
  8. doi request reprint Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America
    Judith A Aberg
    Division of Infectious Diseases and Immunology, New York University School of Medicine, Bellevue Hospital Center, New York
    Clin Infect Dis 58:1-10. 2014
    ..HIV-infected persons should be managed and monitored for all relevant age- and sex-specific health problems. New information based on publications from the period 2009-2013 has been incorporated into this document. ..
  9. ncbi request reprint A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087
    Judith A Aberg
    AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 21:757-67. 2005
    ..Combination therapy with fenofibrate and pravastatin for HIV-related dyslipidemia provides substantial improvements in lipid parameters and appears safe, but is unlikely to achieve all NCEP targets for lipid levels...
  10. ncbi request reprint Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers
    Marshall J Glesby
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 78:143-53. 2005
    ..We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir...
  11. doi request reprint Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268
    Michelle S Cespedes
    New York University School of Medicine, New York, New York
    HIV Clin Trials 14:292-302. 2013
    ..To examine genome-wide associations in HIV-infected women with a history of cervical dysplasia compared with HIV-infected women with no history of abnormal Papanicolaou (Pap) tests...
  12. pmc Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study
    Meagan O'Brien
    Division of Infectious Diseases and Immunology, Cancer Institute, New York University, School of Medicine, New York, NY, USA
    J Acquir Immune Defic Syndr 63:280-8. 2013
    ..We explored whether 1 week of low-dose aspirin attenuates platelet activation and immune activation in HIV-1-infected and virologically suppressed adults on antiretroviral therapy...
  13. ncbi request reprint Aging, inflammation, and HIV infection
    Judith A Aberg
    New York University School of Medicine, New York, NY, USA
    Top Antivir Med 20:101-5. 2012
    ..This article summarizes a presentation by Judith A. Aberg, MD, at the IAS-USA live continuing medical education course held in New York City in October 2011...
  14. pmc Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City
    Saumil Doshi
    Division of Infectious Diseases, Department of Medicine, New York University School of Medicine, 550 First Avenue, BCD, Room 649, New York, NY 10016, USA
    Int J Infect Dis 16:e518-21. 2012
    ..We assessed the incidence of and risk factors for tuberculin skin test (TST) conversion among HIV-infected adults at a New York City clinic...
  15. pmc Case files from the Bellevue Hospital Center at New York University--lipoatrophy following long-term antiretroviral therapy
    Demetre Daskalakis
    Division of Infectious Disease and Immunology, Department of Medicine, New York University School of Medicine Bellevue Hospital, New York, NY, USA
    MedGenMed 7:9. 2005
  16. ncbi request reprint Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy
    Judith A Aberg
    Department of Medicine, Washington University School of Medicine, AIDS Clinical Trials Unit, St Louis, MO, 63108, USA
    Clin Infect Dis 35:E8-E13. 2002
    ..The low rate of these unusual MAC infections does not warrant continuation of primary or secondary prophylaxis after presumed immune reconstitution...
  17. doi request reprint Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America
    Judith A Aberg
    Division of Infectious Diseases and Immunology, New York University School of Medicine, Bellevue Hospital Center, New York
    Clin Infect Dis 58:e1-34. 2014
    ..HIV-infected persons should be managed and monitored for all relevant age- and sex-specific health problems. New information based on publications from the period 2009-2013 has been incorporated into this document. ..
  18. pmc Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York
    Candice K Kwan
    Bellevue Hospital Center, New York City Health and Hospital Corporation, New York, USA
    AIDS Res Hum Retroviruses 28:1025-32. 2012
    ..In HIV-infected patients with severe vitamin D deficiency or hyperparathyroidism, screening for osteomalacia and osteopenia may be warranted...
  19. ncbi request reprint Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial
    Scott M Hammer
    Division of Infectious Diseases, Department of Medicien, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 288:169-80. 2002
    ..Management of antiretroviral treatment failure in patients receiving protease inhibitor (PI)-containing regimens is a therapeutic challenge...
  20. ncbi request reprint Neuropsychiatric complications of antiretroviral therapy
    Michelle S Cespedes
    Division of Infectious Disease, Department of Medicine, New York University School of Medicine, New York, New York 10016, USA
    Drug Saf 29:865-74. 2006
    ..Our intent is to present practitioners with data that can be used in a practical way to both educate and improve outcomes in the HIV-infected patient population...
  21. doi request reprint Coronary heart disease in people infected with HIV
    Carlos D Malvestutto
    New York University Langone Medical Center, New York, USA
    Cleve Clin J Med 77:547-56. 2010
    ..As this population ages, cardiovascular disease is becoming an important cause of morbidity and death. The authors of this review discuss the magnitude and likely mechanisms of the risk and strategies for managing it...
  22. ncbi request reprint Drug-drug interactions with newer antiretroviral agents
    Judith A Aberg
    New York University School of Medicine and Bellevue Hospital Center, New York, NY, USA
    Top HIV Med 16:146-50. 2008
    ....
  23. ncbi request reprint Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals
    Donald Chen
    New York University, Department of Medicine, Division of Infectious Disease, AIDS Clinical Trials Unit, Bellevue C and D Building, Room 558, 550 First Avenue, New York, NY 10016 6481, USA
    Expert Rev Anti Infect Ther 5:921-8. 2007
    ..To date, human trials suggest that pafuramidine is well tolerated overall and has clinical activity against Pneumocystis pneumonia. In this article, we review the available data for the use of pafuramidine in Pneumocystis pneumonia...
  24. pmc Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals
    Benjamin J Eckhardt
    Bellevue Hospital Center, NY City Health and Hospital Corporation, New York, USA
    AIDS Patient Care STDS 26:197-201. 2012
    ..Current antiretroviral (ART) use has significant and variable influence on the relationship between HbA(1c) and FBG. The use of HbA(1c) in conjunction with FBG may be the best modality to screen for diabetes...
  25. pmc Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients
    Christian A Engell
    Department of Medicine, Division of Infectious Diseases and Immunology, New York University School of Medicine at Bellevue Hospital Center, New York, NY 10016, USA
    ISRN Gastroenterol 2011:405390. 2011
    ..There was a significantly greater proportion of naïve patients with suppressed HBV DNA at 24 months. Our results support using initial dual therapy in those with HIV/HBV coinfection...
  26. doi request reprint Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City
    Sapna A Mehta
    Division of Infectious Diseases, Department of Medicine, NewYork University School of Medicine, New York, New York, USA
    Sex Transm Infect 87:344-8. 2011
    ..To understand the factors associated with knowledge of non-occupational post-exposure prophylaxis (nPEP) and pre-exposure prophylaxis (PrEP), bathhouse patrons in New York City (NYC) were surveyed...
  27. pmc A tale of two fungi in a person with HIV
    Jason Faulhaber
    Division of Infectious Diseases and Immunology, New York University School of Medicine, New York, NY, USA
    MedGenMed 8:2. 2006
  28. ncbi request reprint A case of nocardia osteomyelits--is HIV to blame?
    Judith A Aberg
    Washington University, AIDS Clinical Trials Unit, St Louis, USA
    AIDS Read 12:77. 2002